What is FOXO4-DRI?
FOXO4-DRI is a synthetic cell penetrating peptide built from D-amino acids in reverse order so it resists breakdown; it pries the transcription factor FOXO4 off p53 inside senescent cells, which releases p53 to trigger their death. In a 2017 Cell paper it selectively killed senescent cells and restored running capacity, fur density, and kidney function in fast aging and naturally old mice, and later mouse studies reported improved testosterone and sperm production in old males. There is no human trial, no FDA review, and no lawful source; it is prohibited by WADA under section S0.
FOXO4-DRI is a synthetic D-amino acid retro-inverso peptide (about 46 residues) that disrupts the FOXO4 to p53 interaction in senescent cells. It is also known as FOXO4 D-retro-inverso peptide, FOXO4-DRI senolytic, Proxofim, FOXO4 DRI.
How does it work?
In senescent cells, FOXO4 binds p53 in the nucleus and keeps it from triggering apoptosis, which lets damaged cells persist and secrete inflammatory factors (the senescence associated secretory phenotype). FOXO4-DRI is a D-retro-inverso version of the FOXO4 fragment that binds p53; it competes with native FOXO4, freeing p53 to move to mitochondria and start cell death selectively in senescent cells. The D-amino acid backbone resists proteases, which gives it a longer half life than a normal peptide. All of this is shown in cell culture and mice.
| Cluster | Longevity and mitochondrial |
|---|---|
| Routes | Subcutaneous injection (as sold); Intraperitoneal injection (animal studies) |
| Conditions studied | Longevity and healthy aging |
| Record | v3, reviewed, verified Sep 22, 2026 |
What does the evidence say about FOXO4-DRI?
One high profile mouse study and a few follow ups. Baar et al. 2017 showed FOXO4-DRI (5 mg/kg intraperitoneally, 3 doses over a week or repeated cycles) selectively killed senescent cells in culture and in mice, neutralized chemotherapy induced toxicity, and in fast aging XpdTTD/TTD and naturally aged mice restored fur density, running wheel activity, and kidney function markers. Zhang et al. 2020 reported that FOXO4-DRI cleared senescent Leydig cells and raised testosterone in aged mice, and Li et al. 2024 reported improved spermatogenesis in aged mice. No human study of any kind has been published.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 0 | n/a |
| Human observational studies | 0 | n/a |
| Animal studies | 3 | n/a |
| All indexed studies | 3 | n/a |
Human evidence
No indexed human study identified. No pharmacokinetic, safety, or efficacy data in humans exist.
Animal evidence
Baar 2017: in aged and progeroid mice, FOXO4-DRI reduced senescent cell burden and improved fur density, physical activity, and renal function within weeks; in doxorubicin treated mice it reduced chemotherapy toxicity. Zhang 2020: intraperitoneal FOXO4-DRI in aged male mice removed senescent Leydig cells and raised serum testosterone. Li 2024: in aged mice, FOXO4-DRI reduced senescence associated secretory phenotype output from Leydig cells and improved spermatogenesis.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging2017 PMID 28340339 | Cell culture and mouse studies (progeroid and naturally aged mice)Cultured senescent cells; XpdTTD/TTD fast aging mice and naturally aged mice | FOXO4-DRI selectively induced apoptosis in senescent cells, reduced doxorubicin toxicity, and restored fur density, running activity, and kidney function markers in aged mice | Evidence: Animal-only evidence |
| FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice2020 PMID 31959736 | Mouse study with cell culture workAged male mice and cultured Leydig cells | FOXO4-DRI cleared senescent Leydig cells and increased serum testosterone in aged mice | Evidence: Animal-only evidence |
| FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells2024 PMID 39025385 | Mouse studyAged male mice | FOXO4-DRI reduced senescence associated secretory phenotype output and improved spermatogenesis | Evidence: Animal-only evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Longevity and healthy aging | Evidence: Animal-only evidence | Senolytic effects in aged mice; no human data. |
Is FOXO4-DRI legal in the United States?
FDA and compounding status
FOXO4-DRI is not an FDA approved drug and PeptideAgent has not identified it on the FDA 503A bulks nomination lists or in any Pharmacy Compounding Advisory Committee review. Without a listing, a 503A pharmacy has no federal basis to compound it as a bulk substance. It is not eligible for 503B outsourcing. Products sold under this name for human use are unapproved drugs and, because the peptide is long and made entirely of D-amino acids, are expensive and difficult to verify.
WADA status
WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.
Regulatory timeline
No regulatory events recorded.
Full tracker for FOXO4-DRI or the category-wide tracker.
Email me when FOXO4-DRI's status changes
Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.
What published studies of FOXO4-DRI used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Not established in human literature. Mouse studies used 5 mg/kg intraperitoneally, given as 3 doses on alternating days, sometimes repeated in cycles. No human dose, route, or pharmacokinetic study has been published.
Routes reported
| # | Route |
|---|---|
| 1 | Subcutaneous injection (as sold) |
| 2 | Intraperitoneal injection (animal studies) |
What are the side effects and interactions of FOXO4-DRI?
Side effects
| # | Reported side effect |
|---|---|
| 1 | No human safety data of any kind |
| 2 | Theoretical risk that a p53 activating senolytic could harm non-senescent cells or tissues that rely on transient senescence for wound healing |
| 3 | Injection site reactions reported anecdotally |
| 4 | D-amino acid peptides resist degradation, so persistence and immunogenicity in humans are unknown |
Interactions
| # | Interaction |
|---|---|
| 1 | No formal interaction studies exist |
| 2 | Theoretical additive effects with other senolytics (dasatinib, quercetin, fisetin) and with chemotherapy that acts through p53 (not tested) |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Any use outside a clinical trial; no human data exist |
| 2 | Active cancer (p53 pathway manipulation without human data) |
| 3 | Pregnancy and breastfeeding (no data) |
| 4 | Competitive athletes subject to WADA testing (prohibited at all times under S0) |
How do people access FOXO4-DRI legally?
Typical cost: Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Access options
Not available
Not legally available: no approved product, no clinical trials open to the public, and no 503A bulks listing.
Not available
Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.
Access paths are checked against public regulatory records. Products labeled research use only are never listed.
What's actually offered, and what that means for you
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. PeptideAgent has not found an FDA warning letter or review that names FOXO4-DRI. [8] [9] [10]
Being offered does not change the legal status of FOXO4-DRI. FOXO4-DRI is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [4] [11]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [8] [11] [12] [13] [14] [15]
What that means for you
- A pharmacy that compounds FOXO4-DRI is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [8] [12]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [15]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [16]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [17] [18]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [11]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, FOXO4-DRI is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [6]
If you're going ahead anyway
These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound FOXO4-DRI, with or without a prescription. [4]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [19] [20] [21]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [10] [21] [22]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [15] [23] [24] [25] [26] [27]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [15]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [19]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [10]
- Pharmacy: Is this made for me on a prescription written in my name? [22]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [10] [21]
- Prescriber: What is the legal basis for a pharmacy to compound FOXO4-DRI? Is it FDA approved or on the 503A bulks list? [4] [15]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [10]
In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [16]
Frequently asked questions
Is FOXO4-DRI legal in the United States?
It is not an FDA approved drug and is not on the FDA 503A bulks list, so no compounding pharmacy can lawfully make it. Possessing it is not a crime, but selling it for human use is unlawful: the only products available are research chemicals, which are unapproved drugs. It has never been reviewed by FDA's compounding advisory committee. [4] [5] [7]
Does FOXO4-DRI reverse aging?
In mice, it produced striking results: after a short course, aged mice regrew fur, ran more, and improved kidney function markers, and senescent cells were cleared from tissues. In humans, nothing is known, because no study has ever given it to a person. PeptideAgent grades the evidence animal-only. [1]
Does FOXO4-DRI raise testosterone?
Only in old mice so far. A 2020 study found it removed senescent Leydig cells from aged mouse testes and raised serum testosterone, and a 2024 study reported improved sperm production. No human data exist. [2] [3]
What are the side effects of FOXO4-DRI?
Unknown in humans. The mechanism activates p53 driven cell death in senescent cells, and senescent cells play useful roles in wound healing and tumor suppression, so off target harm is a theoretical concern. The D-amino acid design makes the peptide persist longer in the body, and its immunogenicity has never been assessed in people. [1]
How is FOXO4-DRI taken?
In mice it was given by injection into the abdominal cavity on alternating days, sometimes in repeated cycles. Products sold to people are subcutaneous injection vials. There is no human dose, and mouse regimens do not translate to people. PeptideAgent does not give doses for unapproved peptides. [1] [2]
Is FOXO4-DRI banned by WADA?
Yes. FOXO4-DRI has no current approval from any government health authority for human use, so it falls under section S0 (non-approved substances) of the WADA Prohibited List and is prohibited at all times. [6]
FOXO4-DRI vs dasatinib and quercetin: which senolytic is better studied?
Dasatinib plus quercetin has small human pilot trials in diabetic kidney disease and idiopathic pulmonary fibrosis; FOXO4-DRI has none. Both cleared senescent cells in mice. FOXO4-DRI is more selective in cell studies because it targets the FOXO4 to p53 interaction, but that selectivity has never been tested in a person. [1]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Baar MP et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell 2017PubMed 28340339, 2017
- [2]Zhang C et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY) 2020PubMed 31959736, 2020
- [3]Li Y et al. FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. Exp Gerontol 2024PubMed 39025385, 2024
- [4]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [5]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [6]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
- [7]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [8]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
- [9]FDA warning letter 594743, April 1, 2020, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2020
- [10]FDA to telehealth companies: What to know when promoting compounded drugsFDA, 2026
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 22). FOXO4-DRI: evidence, legality, and access. https://peptideagent.ai/peptides/foxo4-dri- HTML link
<a href="https://peptideagent.ai/peptides/foxo4-dri">FOXO4-DRI: evidence, legality, and access</a>, PeptideAgent, updated September 22, 2026.